The primary objective of this multicenter, open-label Phase 2 study is to determine the tumor response of rhIL-12 administered by intravenous injection in patients with advanced malignant melanoma. The secondary objective is to assess the safety of this dose schedule and route of administration.
Showing the most recent 10 out of 859 publications